Clinical Cancer Research

Real-world outcomes of elacestrant in ER+, HER2−, ESR1-mutant metastatic breast cancer

Clinical Cancer Research

The prognostic and predictive impact of ctDNA levels in patients with advanced breast cancer enrolled on the plasmaMATCH trial

Clinical Cancer Research

Clinical and genomic factors associated with elacestrant outcomes in ESR1-mutant metastatic breast cancer open access

ESMO Open

A phase IV prospective study of efficacy and safety of ribociclib and letrozole as first-line therapy in older women (≥70 years) with hormone receptor-positive HER2-negative advanced breast cancer: The RibOB study

Cancer Research and Treatment

Pre-treatment Ki67 index for everolimus efficacy in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer: A multicenter cohort study

Breast Cancer Research

Multiomic profiling of ER-positive HER2-negative breast cancer reveals markers associated with metastatic spread

Cancers

The prognostic and predictive value of body mass index in patients with HR+/HER2- breast cancer treated with CDK4/6 inhibitors: A systematic literature review

Future Oncology

OPERA-01: A phase III study of palazestrant for ER+, HER2- advanced breast cancer after CDK4/6 inhibitor therapy

Journal of Clinical Oncology

Efficacy and safety of elinzanetant for vasomotor symptoms associated with adjuvant endocrine therapy: Phase 3 OASIS 4 trial

Cancers

CDK4/6 inhibitors plus endocrine therapy in early-stage HR+/HER2- breast cancer: Updated meta-analysis of phase III trials